Participants with newly diagnosed Follicular Lymphoma for Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities, Basking Ridge, NJ
Lymphoma+2 More
Mosunetuzumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

Eligible Conditions

  • Lymphoma
  • Follicular Lymphoma ( FL)

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 1 year

Up to 1 year
Overall Response Rate/ORR
Rate of Complete Respons/CR

Trial Safety

Trial Design

1 Treatment Group

Participants with newly diagnosed Follicular Lymphoma
1 of 1
Experimental Treatment

53 Total Participants · 1 Treatment Group

Primary Treatment: Participants with newly diagnosed Follicular Lymphoma · No Placebo Group · Phase 2

Participants with newly diagnosed Follicular Lymphoma
Drug
Experimental Group · 1 Intervention: Mosunetuzumab · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mosunetuzumab
2020
Completed Phase 1
~30

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year
Closest Location: Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities · Basking Ridge, NJ
N/AFirst Recorded Clinical Trial
1 TrialsResearching Lymphoma
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to comply with all the study-related procedures.
You have histologically documented FL of grade 1, 2, or 3A.
You have a bulky tumor that is at least 7 cm in maximum diameter.
The nodal or extranodal mass is greater than 7 cm in maximum diameter.
You have ≥ 3 nodal or extranodal sites each with a diameter ≥ 3 cm.
Fever of unknown etiology.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.